Oncology

Below are the Oncology StripAssay from ViennaLab shown. Somatic pathogenic variants in EGFR, KRAS, BRAF and NRAS genes can influence cancer therapies. Identifying such pathogenic variants in these genes allows for more specific treatments. Genetic variants of genes involved in drug metabolism (e.g. DPYD) can alter the response to chemotherapy. The impact of specific genetic variants is addressed in current guidelines for the type of cancer in question.

PGX-5FU XL StripAssay

Fluoropyrimidines are widely used for the treatment of various solid tumors. The newly launched PGX-5FU XL StripAssay® covers the four most clinically important variants with therapeutic relevance for fluoropyrimidine treatment as recommended by the European Medicines Agency in April 2020. 

Click here for more information.

EGFR XL StripAssay

Mutations in the epidermal growth factor receptor (EGFR) gene are predictive of the response to EGFR tyrosine kinase inhibitors (TKIs). The assays identify 30 EGFR mutations relevant for non-small cell lung cancer (NSCLC) TKI therapy. The EGFR XL StripAssay is an assay for the identification of 30 EGFR mutations in exons 18/19/20/21 based on polymerase chain reaction (PCR) and reverse-hybridization.

FCGR StripAssay

Germline polymorphisms in the Fc gamma receptor (FCGR) gene have been reported to influence antibody-based cancer therapies. The FCGR StripAssay® identifies the variants FCGR2A-H131R and FCGR3A-F158V. An assay for the analysis of Fc gamma receptor (FCGR) polymorphisms based on polymerase chain reaction (PCR) and reverse-hybridization. 

KRAS StripAssay

Monoclonal antibody (mAb) therapies targeting epidermal growth factor receptor (EGFR) are used in metastatic colorectal cancer (mCRC) therapies. KRAS StripAssays® identifies the most relevant genetic variants of KRAS genes interfering with treatment/therapy success. An assay for the identification of 10 KRAS mutations in codons 12 and 13 based on polymerase chain reaction (PCR) and reverse-hybridization.

KRAS-BRAF StripAssay

The KRAS-BRAF StripAssay is an assay for the identification of KRAS and BRAF gene mutations based on polymerase chain reaction (PCR) and reverse-hybridization. It has ultra-sensitive detection of 10 KRAS mutations in codons 12/13 and the BRAF V600E mutation.

KRAS XL StripAssay

Monoclonal antibody (mAb) therapies targeting epidermal growth factor receptor (EGFR) are used in metastatic colorectal cancer (mCRC) therapies. KRAS XL StripAssay® identifies the most relevant genetic variants of KRAS genes interfering with treatment/therapy success. An assay for the identification of 29 KRAS mutations in codons 12/13/59/60/ 61/117/146 based on polymerase chain reaction (PCR) and reverse-hybridization. 

NRAS XL StripAssay

Monoclonal antibody (mAb) therapies targeting epidermal growth factor receptor (EGFR) are used in metastatic colorectal cancer (mCRC) therapies. NRAS StripAssays® identifies the most relevant genetic variants of NRAS genes interfering with treatment/therapy success. An assay for the identification of 22 NRAS mutations in codons 12/13/59/60/ 61/146 based on polymerase chain reaction (PCR) and reverse-hybridization.

BRAF 600/601 StripAssay

Determination of BRAF V600 mutational status is recommended in metastatic colorectal cancer (mCRC) at the same time as RAS mutational status for prognostic assessment (and/or potential selection for clinical trials). BRAF 600/601 StripAssay is an assay for the identification of 9 BRAF mutations in codons 600 and 601 based on polymerase chain reaction (PCR) and reverse-hybridization.

BRAF StripAssay

BRAF gene mutation assessment is indicated in colorectal cancer, advanced non-small-cell lung cancer, melanoma, and thyroid cancer. BRAF StripAssay is an assay for the identification of BRAF p.V600E (c.1799T>A) based on polymerase chain reaction (PCR) and reverse-hybridization.

PGX-TPMT StripAssay

Thiopurine-based therapeutic drugs may accumulate to toxic levels in patients carrying genetic variants of the drug-metabolizing enzyme TPMT. The PGX-TPMT StripAssay® identifies the most frequent TPMT variants of therapeutic relevance. An assay for the identification of TPMT variants *2, *3A, *3B, and *3C  associated with response to thiopurine therapy based on polymerase chain reaction (PCR) and reverse-hybridization. 

Fill in the form

and ask
us anything about our products

After completion, Goffin Molecular Technologies will contact you as soon as possible.